Good info, will need to keep an eye open for other news about leitragin
Good info, will need to keep an eye open for other news about leitragin
If its not Pfizermectin it can't possibly work! (Sarc) The Media/pharma cabal will Ignore and belittle this, its the RUSSIANS!
If its not Pfizermectin it can't possibly work! (Sarc)
The Media/pharma cabal will Ignore and belittle this, its the RUSSIANS!
We have one already they won’t approve it’s a ccr5 inhibitor, that down cycles the inflammation process. It’s has an eua for metastatic cancers and aids, they’ve even tested it out for autoimmune diseases and it works.
Of course it’s being bad mouthed and the fda won’t approve it for covid.
Now, a group of shareholders involved in the failed litigation is taking another approach, through a website called Advancing Leronlimab, to pitch a path forward for the CCR5 antagonist.
The plan suggests that leronlimab could be paired with checkpoint inhibitors like Merck & Co.’s Keytruda, Bristol Myers Squibb’s Opdivo or Roche’s Tecentriq. The plan likens leronlimab to Bristol Myers’ Yervoy, which is often paired with Opdivo. The Big Pharma collects about $1.5 billion a year from the therapy’s combination approvals.
These partner therapies, called immune control point (ICI) inhibitors, act when the tumor begins to resist the main treatment, reactivating the immune system to extend the anti-tumor response.
We have one already they won’t approve it’s a ccr5 inhibitor, that down cycles the inflammation process. It’s has an eua for metastatic cancers and aids, they’ve even tested it out for autoimmune diseases and it works.
Of course it’s being bad mouthed and the fda won’t approve it for covid.
>Now, a group of shareholders involved in the failed litigation is taking another approach, through a website called Advancing Leronlimab, to pitch a path forward for the CCR5 antagonist.
>**The plan suggests that leronlimab could be paired with checkpoint inhibitors like Merck & Co.’s Keytruda, Bristol Myers Squibb’s Opdivo or Roche’s Tecentriq. The plan likens leronlimab to Bristol Myers’ Yervoy, which is often paired with Opdivo. The Big Pharma collects about $1.5 billion a year from the therapy’s combination approvals**.
>These partner therapies, called immune control point (ICI) inhibitors, act when the tumor begins to resist the main treatment, reactivating the immune system to extend the anti-tumor response.
(post is archived)